...
rptx-img

Repare Therapeutics Inc, Common Stock

RPTX

NSQ

$1.77

-$2.2

(-55.42%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$168.77M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
4.66M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.71
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.71 L
$8.49 H
$1.77

About Repare Therapeutics Inc, Common Stock

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; Foundation Medicine, Inc. for the provision of prospective genomic profiling of lunresertib alone or in combinations in genomically-defined patient populations; cooperative research and development agreement with US National Cancer Institute to advance the development of Camonsertib; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRPTXSectorS&P500
1-Week Return-43.81%-2.27%-0.57%
1-Month Return-45.71%-3.96%1.21%
3-Month Return-49.86%-9.7%7.57%
6-Month Return-54.85%-3.37%11.45%
1-Year Return-73.02%3.71%28.48%
3-Year Return-91.28%3.8%29.52%
5-Year Return-94.25%39.78%90.66%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-135.00K7.60M131.83M51.13M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.1,"profit":true},{"date":"2021-12-31","value":5.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.79,"profit":true}]
Cost of Revenue968.00K1.79M3.34M4.18M131.20M[{"date":"2019-12-31","value":0.74,"profit":true},{"date":"2020-12-31","value":1.36,"profit":true},{"date":"2021-12-31","value":2.55,"profit":true},{"date":"2022-12-31","value":3.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(968.00K)(1.65M)4.26M127.65M(80.07M)[{"date":"2019-12-31","value":-0.76,"profit":false},{"date":"2020-12-31","value":-1.29,"profit":false},{"date":"2021-12-31","value":3.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-62.73,"profit":false}]
Gross Margin-(1223.70%)56.00%96.83%(156.59%)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1263.81,"profit":false},{"date":"2021-12-31","value":57.84,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-161.72,"profit":false}]
Operating Expenses26.38M54.44M116.26M151.63M167.36M[{"date":"2019-12-31","value":15.76,"profit":true},{"date":"2020-12-31","value":32.53,"profit":true},{"date":"2021-12-31","value":69.47,"profit":true},{"date":"2022-12-31","value":90.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(26.38M)(54.30M)(108.66M)(19.80M)(116.22M)[{"date":"2019-12-31","value":-2637700000,"profit":false},{"date":"2020-12-31","value":-5430200000,"profit":false},{"date":"2021-12-31","value":-10866000000,"profit":false},{"date":"2022-12-31","value":-1979600000,"profit":false},{"date":"2023-12-31","value":-11622400000,"profit":false}]
Total Non-Operating Income/Expense-(200.00K)333.00K11.53M26.20M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-0.76,"profit":false},{"date":"2021-12-31","value":1.27,"profit":true},{"date":"2022-12-31","value":43.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(27.02M)(54.74M)(108.59M)(13.90M)(103.18M)[{"date":"2019-12-31","value":-2702100000,"profit":false},{"date":"2020-12-31","value":-5474200000,"profit":false},{"date":"2021-12-31","value":-10858600000,"profit":false},{"date":"2022-12-31","value":-1390000000,"profit":false},{"date":"2023-12-31","value":-10317900000,"profit":false}]
Income Taxes195.00K(1.32M)(1.68M)15.15M(9.38M)[{"date":"2019-12-31","value":1.29,"profit":true},{"date":"2020-12-31","value":-8.75,"profit":false},{"date":"2021-12-31","value":-11.08,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-61.95,"profit":false}]
Income After Taxes-(53.42M)(106.91M)(29.05M)(93.80M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5341700000,"profit":false},{"date":"2021-12-31","value":-10690800000,"profit":false},{"date":"2022-12-31","value":-2904700000,"profit":false},{"date":"2023-12-31","value":-9379600000,"profit":false}]
Income From Continuous Operations(27.22M)(53.42M)(106.91M)(29.05M)(97.42M)[{"date":"2019-12-31","value":-2721600000,"profit":false},{"date":"2020-12-31","value":-5341700000,"profit":false},{"date":"2021-12-31","value":-10690800000,"profit":false},{"date":"2022-12-31","value":-2904700000,"profit":false},{"date":"2023-12-31","value":-9742400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(27.22M)(53.42M)(106.91M)(29.05M)(93.80M)[{"date":"2019-12-31","value":-2721600000,"profit":false},{"date":"2020-12-31","value":-5341700000,"profit":false},{"date":"2021-12-31","value":-10690800000,"profit":false},{"date":"2022-12-31","value":-2904700000,"profit":false},{"date":"2023-12-31","value":-9379600000,"profit":false}]
EPS (Diluted)-(4.09)(2.82)(0.78)(2.23)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-409,"profit":false},{"date":"2021-12-31","value":-282,"profit":false},{"date":"2022-12-31","value":-78,"profit":false},{"date":"2023-12-31","value":-223,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RPTX
Cash Ratio 5.77
Current Ratio 6.45

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RPTX
ROA (LTM) -23.39%
ROE (LTM) -41.17%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RPTX
Debt Ratio Lower is generally better. Negative is bad. 0.15
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.85

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RPTX
Trailing PE NM
Forward PE NM
P/S (TTM) 2.54
P/B 0.87
Price/FCF NM
EV/R 0.02
EV/Ebitda 0.58

FAQs

What is Repare Therapeutics Inc share price today?

Repare Therapeutics Inc (RPTX) share price today is $1.77

Can Indians buy Repare Therapeutics Inc shares?

Yes, Indians can buy shares of Repare Therapeutics Inc (RPTX) on Vested. To buy Repare Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RPTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Repare Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Repare Therapeutics Inc (RPTX) via the Vested app. You can start investing in Repare Therapeutics Inc (RPTX) with a minimum investment of $1.

How to invest in Repare Therapeutics Inc shares from India?

You can invest in shares of Repare Therapeutics Inc (RPTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in RPTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Repare Therapeutics Inc shares
What is Repare Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Repare Therapeutics Inc (RPTX) is $8.49. The 52-week low price of Repare Therapeutics Inc (RPTX) is $2.71.

What is Repare Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Repare Therapeutics Inc (RPTX) is

What is Repare Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Repare Therapeutics Inc (RPTX) is 0.87

What is Repare Therapeutics Inc dividend yield?

The dividend yield of Repare Therapeutics Inc (RPTX) is 0.00%

What is the Market Cap of Repare Therapeutics Inc?

The market capitalization of Repare Therapeutics Inc (RPTX) is $168.77M

What is Repare Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Repare Therapeutics Inc is RPTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top